Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An update from Argenx Se ( (ARGX) ) is now available.
On October 15, 2025, Argenx SE announced its participation in the 2025 AANEM Annual Meeting and MGFA Scientific Session, where it will present pivotal data on VYVGART and empasiprubart. The company highlighted the potential of VYVGART in treating myasthenia gravis and other neuromuscular diseases, showcasing results from various studies that demonstrate its efficacy and safety. This presentation underscores Argenx’s commitment to advancing innovative therapies and improving patient outcomes in the field of autoimmune and neuromuscular diseases.
The most recent analyst rating on (ARGX) stock is a Buy with a $800.00 price target. To see the full list of analyst forecasts on Argenx Se stock, see the ARGX Stock Forecast page.
Spark’s Take on ARGX Stock
According to Spark, TipRanks’ AI Analyst, ARGX is a Outperform.
Argenx Se’s strong financial performance and positive earnings call sentiment are the primary drivers of its stock score. The company’s robust revenue growth and strategic pipeline advancements are significant strengths. However, technical indicators suggest the stock may be overbought, and its high valuation poses a risk. Operational efficiency and cash flow challenges remain areas for improvement.
To see Spark’s full report on ARGX stock, click here.
More about Argenx Se
Argenx SE is a global immunology company focused on developing treatments for severe autoimmune diseases. The company is known for its innovative therapies, including VYVGART, which targets a broad range of neuromuscular diseases, and its pipeline candidate empasiprubart.
Average Trading Volume: 382,662
Technical Sentiment Signal: Buy
Current Market Cap: $49.9B
For a thorough assessment of ARGX stock, go to TipRanks’ Stock Analysis page.